Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?

Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M, Giovannucci EL, Rubin MA, Mucci LA.

J Clin Oncol. 2009 Jul 20;27(21):3459-64. doi: 10.1200/JCO.2008.20.4669. Epub 2009 May 11.

2.

The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival.

Nguyen CT, Reuther AM, Stephenson AJ, Klein EA, Jones JS.

J Urol. 2009 Jan;181(1):75-80. doi: 10.1016/j.juro.2008.09.027. Epub 2008 Nov 13.

PMID:
19012927
3.

Age and grade trends in prostate cancer (1974-2003): a Surveillance, Epidemiology, and End Results Registry analysis.

Jani AB, Johnstone PA, Liauw SL, Master VA, Brawley OW.

Am J Clin Oncol. 2008 Aug;31(4):375-8. doi: 10.1097/COC.0b013e3181637384.

PMID:
18845997
4.

Explaining the race difference in prostate cancer stage at diagnosis.

Jones BA, Liu WL, Araujo AB, Kasl SV, Silvera SN, Soler-Vilá H, Curnen MG, Dubrow R.

Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2825-34. doi: 10.1158/1055-9965.EPI-08-0203. Epub 2008 Sep 30.

5.

Prostate-specific antigen screening among young men in the United States.

Scales CD Jr, Antonelli J, Curtis LH, Schulman KA, Moul JW.

Cancer. 2008 Sep 15;113(6):1315-23. doi: 10.1002/cncr.23667.

6.

Use of the prostate-specific antigen test among U.S. men: findings from the 2005 National Health Interview Survey.

Ross LE, Berkowitz Z, Ekwueme DU.

Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):636-44. doi: 10.1158/1055-9965.EPI-07-2709.

7.

Cancer statistics, 2008.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ.

CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.

8.

Contemporary trends in low risk prostate cancer: risk assessment and treatment.

Cooperberg MR, Broering JM, Kantoff PW, Carroll PR.

J Urol. 2007 Sep;178(3 Pt 2):S14-9. Epub 2007 Jul 20.

9.

Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24.

Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, Rafnar T, Bergthorsson JT, Agnarsson BA, Baker A, Sigurdsson A, Benediktsdottir KR, Jakobsdottir M, Xu J, Blondal T, Kostic J, Sun J, Ghosh S, Stacey SN, Mouy M, Saemundsdottir J, Backman VM, Kristjansson K, Tres A, Partin AW, Albers-Akkers MT, Godino-Ivan Marcos J, Walsh PC, Swinkels DW, Navarrete S, Isaacs SD, Aben KK, Graif T, Cashy J, Ruiz-Echarri M, Wiley KE, Suarez BK, Witjes JA, Frigge M, Ober C, Jonsson E, Einarsson GV, Mayordomo JI, Kiemeney LA, Isaacs WB, Catalona WJ, Barkardottir RB, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K.

Nat Genet. 2007 May;39(5):631-7. Epub 2007 Apr 1.

PMID:
17401366
10.

A common variant associated with prostate cancer in European and African populations.

Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, Sigurdsson A, Benediktsdottir KR, Cazier JB, Sainz J, Jakobsdottir M, Kostic J, Magnusdottir DN, Ghosh S, Agnarsson K, Birgisdottir B, Le Roux L, Olafsdottir A, Blondal T, Andresdottir M, Gretarsdottir OS, Bergthorsson JT, Gudbjartsson D, Gylfason A, Thorleifsson G, Manolescu A, Kristjansson K, Geirsson G, Isaksson H, Douglas J, Johansson JE, Bälter K, Wiklund F, Montie JE, Yu X, Suarez BK, Ober C, Cooney KA, Gronberg H, Catalona WJ, Einarsson GV, Barkardottir RB, Gulcher JR, Kong A, Thorsteinsdottir U, Stefansson K.

Nat Genet. 2006 Jun;38(6):652-8. Epub 2006 May 7.

PMID:
16682969
11.

Prostate cancer and the Will Rogers phenomenon.

Albertsen PC, Hanley JA, Barrows GH, Penson DF, Kowalczyk PD, Sanders MM, Fine J.

J Natl Cancer Inst. 2005 Sep 7;97(17):1248-53.

PMID:
16145045
12.

Radical prostatectomy versus watchful waiting in early prostate cancer.

Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson SO, Bratell S, Spångberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO, Norlén BJ, Johansson JE; Scandinavian Prostate Cancer Group Study No. 4.

N Engl J Med. 2005 May 12;352(19):1977-84.

13.

The changing face of low-risk prostate cancer: trends in clinical presentation and primary management.

Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR.

J Clin Oncol. 2004 Jun 1;22(11):2141-9.

14.

Prostate cancer grade assignment: the effect of chronological, interpretive and translation bias.

Kondylis FI, Moriarty RP, Bostwick D, Schellhammer PF.

J Urol. 2003 Oct;170(4 Pt 1):1189-93.

PMID:
14501722
15.

Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF.

Med Care. 2002 Aug;40(8 Suppl):IV-3-18.

PMID:
12187163
16.

Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.

D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP.

Cancer. 2002 Jul 15;95(2):281-6.

17.

American Cancer Society guidelines for the early detection of cancer.

Smith RA, Cokkinides V, von Eschenbach AC, Levin B, Cohen C, Runowicz CD, Sener S, Saslow D, Eyre HJ; American Cancer Society.

CA Cancer J Clin. 2002 Jan-Feb;52(1):8-22.

18.

Combined-modality staging for localized adenocarcinoma of the prostate.

D'Amico AV.

Oncology (Williston Park). 2001 Aug;15(8):1049-59; discussion 1060-2, 1064-5, 1069-70,1073-5. Review.

19.

Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study.

Hoffman RM, Gilliland FD, Eley JW, Harlan LC, Stephenson RA, Stanford JL, Albertson PC, Hamilton AS, Hunt WC, Potosky AL.

J Natl Cancer Inst. 2001 Mar 7;93(5):388-95.

PMID:
11238701
20.

Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy.

Chan TY, Partin AW, Walsh PC, Epstein JI.

Urology. 2000 Nov 1;56(5):823-7.

PMID:
11068310

Supplemental Content

Support Center